Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6CBP

Crystal structure of the single chain variable fragment of the DH270.6 bnAb in complex with the Man9-V3 glycopeptide

Summary for 6CBP
Entry DOI10.2210/pdb6cbp/pdb
Related6CBJ
Related PRD IDPRD_900111
DescriptorMan9-V3 glycopeptide, DH270.6 single chain variable fragment, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
Functional Keywordsfab fragment, hiv-1, antibody, glycopeptide, immune system
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight33172.04
Authors
Fera, D.,Harrison, S.C. (deposition date: 2018-02-03, release date: 2018-02-21, Last modification date: 2024-11-13)
Primary citationFera, D.,Lee, M.S.,Wiehe, K.,Meyerhoff, R.R.,Piai, A.,Bonsignori, M.,Aussedat, B.,Walkowicz, W.E.,Ton, T.,Zhou, J.O.,Danishefsky, S.,Haynes, B.F.,Harrison, S.C.
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.
Nat Commun, 9:1111-1111, 2018
Cited by
PubMed Abstract: HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide ("Man-V3") for structural studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody (bnAb) lineage ("DH270"), to visualize the epitope on Env and to study how affinity maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man-V3 encompasses two key features of the V3 region recognized by V3-glycan bnAbs-the conserved GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1 Env trimer. An additional structure identifies roles for two critical mutations in the development of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine immunogen.
PubMed: 29549260
DOI: 10.1038/s41467-018-03565-6
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.17 Å)
Structure validation

231029

PDB entries from 2025-02-05

PDB statisticsPDBj update infoContact PDBjnumon